A Phase 1, randomized, fixed sequence study to evaluate the effect of multiple dose administration of modified release diltiazem on the multiple dose pharmacokinetics of CP-945,598 in healthy overweight and obese subjects.
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2009
At a glance
- Drugs Diltiazem; Otenabant
- Indications Coronary artery disease; Hypertension; Obesity
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 18 Sep 2009 Actual initiation date changed from Apr 2007 to Mar 2007 as reported by ClinicalTrials.gov.
- 15 Apr 2008 New trial record.